CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder

Overview

CDKL5 deficiency disorder (CDD) is a rare X-linked neurodevelopmental disorder caused by pathogenic variants in the [CDKL5](/entities/cdkl5) gene (cyclin-dependent kinase-like 5). CDD is characterized by early-onset seizures (typically within the first 3 months of life), profound developmental impairment, and multisystem involvement including cortical visual impairment, motor dysfunction, and autonomic abnormalities. The disorder predominantly affects females (due to X-linked inheritance), though males with pathogenic variants tend to have more severe phenotypes.

CDKL5 was first implicated in disease in 2004, and CDD has since been recognized as a distinct entity within the expanding landscape of developmental and epileptic encephalopathies (DEEs). Estimated prevalence ranges from 1:40,000 to 1:100,000 live births, though underdiagnosis likely means the true burden is higher[@cdkl5review2022].

Genetics and Molecular Basis

CDKL5 Gene

[CDKL5](/entities/cdkl5) is located on the X chromosome (Xp22.13) and encodes a serine-threonine kinase with high expression in the developing brain, particularly in neurons. The protein is structurally related to cyclin-dependent kinases (CDKs) but has a unique C-terminal region. CDKL5 plays critical roles in:

CDKL5 Deficiency Disorder

Overview

CDKL5 deficiency disorder (CDD) is a rare X-linked neurodevelopmental disorder caused by pathogenic variants in the [CDKL5](/entities/cdkl5) gene (cyclin-dependent kinase-like 5). CDD is characterized by early-onset seizures (typically within the first 3 months of life), profound developmental impairment, and multisystem involvement including cortical visual impairment, motor dysfunction, and autonomic abnormalities. The disorder predominantly affects females (due to X-linked inheritance), though males with pathogenic variants tend to have more severe phenotypes.

CDKL5 was first implicated in disease in 2004, and CDD has since been recognized as a distinct entity within the expanding landscape of developmental and epileptic encephalopathies (DEEs). Estimated prevalence ranges from 1:40,000 to 1:100,000 live births, though underdiagnosis likely means the true burden is higher[@cdkl5review2022].

Genetics and Molecular Basis

CDKL5 Gene

[CDKL5](/entities/cdkl5) is located on the X chromosome (Xp22.13) and encodes a serine-threonine kinase with high expression in the developing brain, particularly in neurons. The protein is structurally related to cyclin-dependent kinases (CDKs) but has a unique C-terminal region. CDKL5 plays critical roles in:

Over 200 pathogenic variants have been described, distributed across the gene:

• Missense variants (~40%): mostly in the kinase domain
• Nonsense/frameshift variants (~45%): C-terminal truncations common
• Splice variants (~10%): aberrant mRNA processing
• Larger deletions (~5%): encompassing CDKL5 and neighboring genes

Pathophysiology

CDKL5 loss-of-function disrupts multiple brain processes:

The early onset (in utero or first months) means CDKL5 dysfunction disrupts the earliest stages of circuit formation, leading to severe and likely irreversible developmental impairment.

Clinical Presentation

Neonatal and Early Infant Period (0–6 months)

• Seizure onset typically 2-6 weeks of life (often before 3 months)
• Initial seizure types: tonic (spasms), clonic, or focal seizures
• EEG often shows burst suppression or poorly organized background
• Development initially appears normal but plateaus early

Infancy and Early Childhood (6 months – 5 years)

Multiple seizure types emerge:

• Tonic seizures (spasm-like): most common type
• Myoclonic seizures: sudden jerks
• Focal seizures: with or without generalization
• Atypical absence seizures: staring spells
• Electrical status epilepticus during sleep (ESES) in ~50%
• Epileptic spasms (infantile spasms): in ~40%

Additional features:

• Cortical visual impairment (CVI): severe visual dysfunction not explained by eye abnormalities — affects >70%
• Hypotonia: generalized low muscle tone
• Hand-wringing stereotypies: repetitive, rhythmic hand movements characteristic
• Gastrointestinal dysfunction: feeding difficulties, constipation, GER

Childhood and Beyond

Seizure patterns evolve but persist. Developmental impairment is profound:

• Most patients non-ambulatory or have unstable gait
• Limited or no language (most use non-verbal communication)
• Severe intellectual disability across all domains
• High rates of autism spectrum features (>70%)
• Scoliosis, osteoporosis, and fractures common
• Autonomic dysfunction: breathing irregularities, temperature dysregulation

Diagnosis

Clinical Diagnostic Features

Genetic Confirmation

• X-linked epilepsy panel: tests CDKL5 and related genes
• Whole exome sequencing: identifies CDKL5 variants (female probands)
• Targeted CDKL5 sequencing: if clinical suspicion is high
• Karyotype/ microarray: detects larger deletions encompassing CDKL5

EEG Patterns

• Early EEG may show burst suppression or discontinuous pattern
• Later: focal or multifocal epileptiform discharges
• ESES (electrical status epilepticus during sleep) in ~50%
• Background slowing and disorganization progressive

Treatment

Anti-Seizure Medications

| Drug | Evidence | Notes |
|------|---------|-------|
| Cannabidiol (Epidiolex) | Moderate | FDA-approved for seizures in CDKL5; positive Phase 3 data[@cdkl5review2022] |
| Benzodiazepines (clobazam) | Low-moderate | Common adjunct; tachyphylaxis limits use |
| Valproic acid | Low-moderate | First-line in many centers |
| Vigabatrin | Low | May help infantile spasms |
| Levetiracetam | Low | Widely used; limited efficacy |
| Everolimus (mTOR inhibitor) | Low | May help some patients with mTOR pathway involvement |

Cannabidiol received FDA approval for CDKL5 deficiency disorder in 2020, making it one of the few disorder-specific therapies.

Non-Pharmacologic

• Ketogenic diet: may help seizures; used in refractory cases
• Vagus nerve stimulation (VNS): seizure reduction in some patients
• Corticosteroids/ACTH: for infantile spasms component
• Physical therapy: prevent contractures, maintain mobility as possible
• Vision therapy: maximize use of remaining vision

Gene Therapy

CDKL5 is an important target for gene therapy given:

• X-linked inheritance (one copy needed for therapeutic effect)
• Gene size (~4.5kb coding) fits within AAV packaging limits
• Early intervention before irreversible developmental damage is critical

Prognosis

| Outcome | Details |
|---------|---------|
| Seizure outcome | Seizures typically persist but may reduce in frequency with age |
| Cognitive outcome | 100% severe to profound ID; communication very limited |
| Motor | Most non-ambulatory or require extensive support; scoliosis common |
| Visual | Cortical visual impairment persists; affects all domains |
| Life expectancy | Not well established; males often more severe; respiratory issues common |
| Quality of life | Significant impairment; many patients require full-time care |

References